CARBALIVE | Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.
01-05-2015
-31-01-2021
Show more information
Organisation
A2F ASSOCIATES LIMITED